SATURDAY, May 30 — The current use of combined hormone replacement therapy (HRT) is associated with a higher risk of dying for women diagnosed with non-small cell lung cancer, a new study shows.
The risk was highest in current smokers, less high…
SATURDAY, May 30 — Certain drugs offer incremental yet significant improvements in pushing back advanced lung cancer.
That’s the conclusion of studies presented Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in…
SATURDAY, May 30 –A vaccine for advanced melanoma has shown promise in a new study.
Melanoma is the most serious type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In…
SATURDAY, May 30 — A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.
In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib…
SATURDAY, May 30 — The cancer drug Avastin, widely used for lung, breast and metastatic colorectal cancers, appears ineffective for patients with early stage colon cancer, a result the trial’s lead author called “disappointing.”
“There’s no sense…
SATURDAY, May 30 — Following the example of professional movers can help you reduce the risk of injury the next time you move, says a new study that included 20 men who carried a load on a treadmill so that researchers could assess the effects on…
SATURDAY, May 30 –Surgery is no longer the best treatment option for most patients with advanced colorectal cancer that has spread to other organs, a new study suggests.
Immediate colon resection (surgical removal) following diagnosis of stage IV…
UroToday.com – This updated review of tadalafil (Cialis), one of the three available phosphodiesterase type 5 (PDE5) inhibitors that revolutionized the treatment of erectile dysfunction (ED), analyzes its latest clinical studies. Tadalafil’s most unique and identifying characteristic is its long half-life of 17.5 hours, compared with 4 hours for sildenafil (Viagra) and vardenafil (Levitra).
Lees meer..
GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment.
Lees meer..
Bayer Healthcare Pharmaceuticals Inc. announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. “We are excited to see that several studies of Leukine have been accepted at ASCO,” said Pam Cyrus, MD, vice president, Medical Affairs, Oncology, Bayer HealthCare Pharmaceuticals.
Lees meer..